Navigation Links
Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis

LAIYANG, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the American Arbitration Association ("AAA") rendered a decision rejecting requests by Capital Research Group, Inc. ("CRG") to award it $13.8 million and by Capital Research Group Partners, Inc. ("CRGP") to award it $13.7 million related to an alleged breach of three consulting agreements.

On February 2, 2009, after the arbitration panel heard CRG and CRGP's claims, and Genesis' counterclaims, the panel awarded a net total of $980,070.50 to CRG and CRGP jointly, representing less than four percent (4%) of the damages sought by Claimants. The AAA also denied the Claimants' requests for costs and pre-judgment interest, stating that once the award was satisfied, CRG and CRGP would have no further claims against Genesis stock or other property that were the subject of the arbitration.

A few days before the decision by the AAA, all remaining demands for arbitration filed against Genesis by related parties China West, LLC and China West II, LLC were withdrawn.

"While we are disappointed that any damages would be levied against the Company, we believe that this outcome has resulted in minimal negative impact on Genesis," said Mr. Wubo Cao, CEO of Genesis. "The successful defense of CRG and CRGP's claims, along with the withdrawal by China West and China West II of their remaining demands for arbitration will allow us to once again turn our full attention to managing and growing Genesis."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    Genesis Pharmaceuticals Enterprises, Inc.
     Ms. Elsa Sung, CFO
     Phone:    +1-954-727-8435
     Web site:

     CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone:    +1-646-213-1915
     Web site:

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
2. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
3. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
4. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
5. What is the pathogenesis of C. jejuni-related disease?
6. ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention
7. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
8. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
9. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
10. Organogenesis Receives Two Prestigious Awards for Economic Impact and Manufacturing Excellence
11. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: